{
  "consolidation_metadata": {
    "timestamp": "2025-10-02T16:12:50.136096",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "picos",
    "data_split": "test",
    "total_consolidated_picos": 28,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy for which docetaxel is the appropriate patient-individual therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy for which docetaxel is the appropriate patient-individual therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "patient-individual therapy, taking into account previous therapy and histology with selection of afatinib, pemetrexed, erlotinib, docetaxel in combination with ramucirumab, docetaxel in combination with nintedanib and vinorelbine",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy or after sequential therapy with an anti-PD-1/PD-L1 and platinum-containing chemotherapy for whom a therapy other than docetaxel is the appropriate patient-individual therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "patient-individual therapy, taking into account previous therapy and histology with selection of afatinib, pemetrexed, erlotinib, docetaxel in combination with ramucirumab, docetaxel in combination with nintedanib and vinorelbine"
      }
    },
    {
      "Population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pemetrexed"
      }
    },
    {
      "Population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "nivolumab"
      }
    },
    {
      "Population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pembrolizumab"
      }
    },
    {
      "Population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab"
      }
    },
    {
      "Population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel in combination with nintedanib",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel in combination with nintedanib"
      }
    },
    {
      "Population": "advanced NSCLC patients with KRAS G12C mutation who have received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "advanced NSCLC patients with KRAS G12C mutation who have received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "advanced NSCLC patients with KRAS G12C mutation who have received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "standard of care therapy",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "advanced NSCLC patients with KRAS G12C mutation who have received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "standard of care therapy"
      }
    },
    {
      "Population": "previously treated KRAS G12C mutation-positive advanced NSCLC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "previously treated KRAS G12C mutation-positive advanced NSCLC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "previously treated KRAS G12C mutation-positive advanced NSCLC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel plus nintedanib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "previously treated KRAS G12C mutation-positive advanced NSCLC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel plus nintedanib"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation whose disease has progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation whose disease has progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation whose disease has progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemotherapy",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation whose disease has progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "chemotherapy"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation whose disease has progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "immunotherapy",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell bronchial cancer (NSCBC) with the KRAS G12C mutation whose disease has progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "immunotherapy"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel + nintedanib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with mutated KRAS G12C and who have progressed after at least one prior systemic line of therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel + nintedanib"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, in case of progression after at least one previous line of systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel monotherapy",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, in case of progression after at least one previous line of systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel monotherapy"
      }
    },
    {
      "Population": "patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, who have progressed after at least one prior line of systemic therapy and have been treated with docetaxel or who are not medically suitable for treatment with Docetaxel",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation, who have progressed after at least one prior line of systemic therapy and have been treated with docetaxel or who are not medically suitable for treatment with Docetaxel",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated according to Failure of at least one systemic therapy Targeted therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Sotorasib",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation should be treated according to Failure of at least one systemic therapy Targeted therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Sotorasib"
      }
    },
    {
      "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sotorasib"
      }
    },
    {
      "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "patients with active KRAS G12C and 0-2 performance status and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with active KRAS G12C and 0-2 performance status and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sotorasib"
      }
    },
    {
      "Population": "patients with active KRAS G12C and 0-2 performance status and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with active KRAS G12C and 0-2 performance status and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "adagrasib"
      }
    },
    {
      "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel"
      }
    },
    {
      "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel plus nintedanib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "docetaxel plus nintedanib"
      }
    },
    {
      "Population": "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "adagrasib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "adagrasib"
      }
    },
    {
      "Population": "patients with the KRAS G12C mutation are recommended treatment with sotorbasin following progression from prior systemic cytostatic and/or immune cell therapies",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorbasin",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with the KRAS G12C mutation are recommended treatment with sotorbasin following progression from prior systemic cytostatic and/or immune cell therapies",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sotorbasin"
      }
    }
  ]
}